REGULUS THERAPEUTICS INC.

(RGLS)
  Report
Delayed Nasdaq  -  04:00 2022-08-05 pm EDT
1.610 USD   -5.29%
08/04Regulus Therapeutics Announces Timing for Second Quarter 2022 Financial Results Webcast and Conference Call
PR
07/15REGULUS THERAPEUTICS INC. : Other Events (form 8-K)
AQ
06/29REGULUS THERAPEUTICS INC. : REVERSE SPLIT: 1 of 10
FA
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Regulus Therapeutics Gets FDA Orphan Designation for RGLS8429

06/21/2022 | 06:38am EDT

By Colin Kellaher


The U.S. Food and Drug Administration granted orphan-drug designation to Regulus Therapeutics Inc.'s RGLS8429 for the treatment of autosomal dominant polycystic kidney disease, a leading cause of end-stage renal disease, the company said Tuesday.

There are currently limited treatment options for autosomal dominant polycystic kidney disease, which affects nearly 160,000 people in the U.S., with about half of patients developing end-stage renal disease by age 60 requiring dialysis or transplantation, the San Diego clinical-stage biopharmaceutical company said.

The FDA's orphan-drug program gives special status to drugs and biologics for diseases and disorders that affect fewer than 200,000 people in the U.S. and provides for an extended marketing exclusivity period against competition.

Regulus is currently conducting a Phase 1 single-ascending dose study in healthy volunteers to assess safety, tolerability and pharmacokinetics of RGLS8429.


Write to Colin Kellaher at colin.kellaher@wsj.com


(END) Dow Jones Newswires

06-21-22 0838ET

All news about REGULUS THERAPEUTICS INC.
08/04Regulus Therapeutics Announces Timing for Second Quarter 2022 Financial Results Webcast..
PR
07/15REGULUS THERAPEUTICS INC. : Other Events (form 8-K)
AQ
06/29REGULUS THERAPEUTICS INC. : REVERSE SPLIT: 1 of 10
FA
06/28Wall Street Set to Open Higher
MT
06/28Top Premarket Decliners
MT
06/27REGULUS THERAPEUTICS INC. : Material Modification to Rights of Security Holders, Financial..
AQ
06/21Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for ..
PR
06/21Regulus Therapeutics Announces Receipt of FDA Orphan Drug Designation for RGLS8429 for ..
CI
06/21Regulus Therapeutics Gets FDA Orphan Designation for RGLS8429
DJ
06/13REGULUS THERAPEUTICS INC. : Change in Directors or Principal Officers, Submission of Matte..
AQ
More news
Analyst Recommendations on REGULUS THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -28,6 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,93x
Yield 2022 -
Capitalization 23,5 M 23,5 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 11,3x
Nbr of Employees 25
Free-Float 9,47%
Chart REGULUS THERAPEUTICS INC.
Duration : Period :
Regulus Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGULUS THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Last Close Price 1,61 $
Average target price 14,00 $
Spread / Average Target 770%
EPS Revisions
Managers and Directors
Joseph P. Hagan President, Chief Executive Officer & Director
Crispina Calsada Chief Financial Officer
Stelios Papadopoulos Chairman
Denis Drygin Chief Scientific Officer
David Baltimore Independent Director
Sector and Competitors
1st jan.Capi. (M$)
REGULUS THERAPEUTICS INC.-48.89%24
GILEAD SCIENCES, INC.-15.87%76 626
VERTEX PHARMACEUTICALS31.16%73 868
REGENERON PHARMACEUTICALS, INC.-2.84%65 600
BIONTECH SE-28.97%44 499
WUXI APPTEC CO., LTD.-19.26%41 093